Ginkgo Bioworks (DNA) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ginkgo Bioworks (DNA) has outperformed Sana Biotechnology (SANA) over the past year, losing 29.5% versus a loss of 38.4%. Over five years, SANA leads with a -86.6% price change compared with -97.6% for DNA. Ginkgo Bioworks is the larger company by market cap ($884.9 million vs $853.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | SANA |
|---|---|---|
| Share price | $13.14 | $2.85 |
| Market cap | $884.85M | $853.18M |
| 1-day change | +15.87% | +2.15% |
| YTD return | +36.46% | -31.45% |
| 1-year return | -29.52% | -38.41% |
| 5-year return | -97.62% | -86.58% |
| EPS (TTM) | $-5.06 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $6.55 |
| 52-week low | $5.37 | $2.61 |
| Distance from 52-week high | -27.88% | -56.49% |
| Analyst consensus | none | none |
| Avg. price target upside | -46.73% | +195.79% |
| Average volume | 1.80M | 3.13M |
| Shares outstanding | 55.38M | 299.36M |
| Employees | 485 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
DNA vs SANA FAQ
Which is bigger, Ginkgo Bioworks or Sana Biotechnology?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $884.85M compared with $853.18M for Sana Biotechnology (SANA).
Which stock has performed better over the past year, DNA or SANA?
DNA returned -29.52% over the past 12 months, compared with -38.41% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.